Dec. 9, 2024 — Researchers used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time.

Tumors are the result of abnormal cell growth. Usually, the cells in your body grow and divide to form new cells whenever your body needs them. When older cells die, they’re replaced by new ones.

For teratomas and non-germinomatous germ cell tumors (NGGCTs), our approach was 1–2 cycles of chemotherapy (carboplatin or cisplatin + etoposide + ifosfamide), followed by surgery, additional ...

The single-cell analysis revealed a diverse range of cell types within the tumor microenvironment (TME), including tumor cells, immune cells, and fibroblasts, with varying proportions across cases.

However, their effectiveness has plateaued due to therapeutic resistance that renders tumor-infiltrating lymphocytes ... Additionally, pharmacologic inhibition of T cell glycolysis under hypoxia ...

to trigger T-cell activation and tumor cell lysis, with minimal release of cytokines. Some of the major obstacles to cellular immunotherapy in solid tumors include inefficient cell infiltration into ...

Having a larger amount of LPCs in the bloodstream aids cancer cell replication, thus helping tumors grow. “When you eat an excessive amount of food, your body converts it into fat,” Patti ...

For the first time, researchers have used lab-grown organoids created from tumors of individuals with glioblastoma (GBM) to accurately model a patient's response to CAR T cell therapy in real time.

The researchers created organoids from the tumors of patients with recurrent glioblastoma who underwent surgery as part of a Phase I clinical trial for a dual-target CAR-T cell therapy.